IDEAYA Biosciences (NASDAQ:IDYA) Given “Buy” Rating at Guggenheim

Guggenheim reissued their buy rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note released on Wednesday,Benzinga reports. They currently have a $50.00 target price on the stock.

IDYA has been the subject of a number of other research reports. Truist Financial raised their price objective on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. BTIG Research reissued a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, October 21st. JPMorgan Chase & Co. upped their price objective on IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Mizuho raised their target price on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada boosted their target price on shares of IDEAYA Biosciences from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.60.

IDEAYA Biosciences Trading Up 0.5%

Shares of IDYA stock opened at $30.92 on Wednesday. The company has a market capitalization of $2.71 billion, a P/E ratio of -23.60 and a beta of 0.10. The business’s 50 day moving average is $34.25 and its two-hundred day moving average is $30.44. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.09. The company had revenue of $21.75 million for the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter last year, the company earned ($1.49) EPS. IDEAYA Biosciences’s revenue for the quarter was up 55.7% compared to the same quarter last year. As a group, equities analysts predict that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

A number of large investors have recently made changes to their positions in IDYA. Farther Finance Advisors LLC grew its stake in IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after acquiring an additional 580 shares during the period. ANTIPODES PARTNERS Ltd boosted its holdings in shares of IDEAYA Biosciences by 49.4% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of IDEAYA Biosciences in the third quarter valued at $38,000. Global Retirement Partners LLC acquired a new position in IDEAYA Biosciences in the fourth quarter valued at $61,000. Finally, Abich Financial Wealth Management LLC acquired a new position in IDEAYA Biosciences in the third quarter valued at $58,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences News Roundup

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results beat expectations: EPS loss was narrower than consensus (‑$0.94 vs. ‑$1.03 est.) and revenue came in well above estimates at $21.75M (vs. ~$5.95M est.), with revenue up ~56% year‑over‑year — a tangible near-term fundamental beat. Q4 Press Release
• Positive Sentiment: Pipeline and readout timing bolsters near-term catalyst visibility: 130 required PFS events were confirmed by BICR in the Phase 2/3 OptimUM‑02 darovasertib + crizotinib trial and topline results are expected by roughly the last week of March; darovasertib is planned for three randomized Phase 3 registrational trials by H1 2026. Business Update / PR Newswire
• Positive Sentiment: ADC program (IDE849) progress and milestones: company expects to initiate a registrational IDE849 monotherapy study in 2L+ SCLC/NEC by end of 2026 and to provide preliminary IDE849 Phase 1 data by year‑end — potential medium‑term value drivers if clinical data are positive. Business Update / PR Newswire
• Positive Sentiment: Strong balance sheet: ~ $1.05B in cash, cash equivalents and marketable securities as of 12/31/2025, which management says should fund operations into 2030 — lowers near‑term financing risk. Business Update / PR Newswire
• Positive Sentiment: Analyst price-target lifts: Wedbush raised its target to $52 (outperform), Guggenheim reaffirmed buy with $50 PT, and RBC reaffirmed outperform with a $49 PT — these raise upside expectations and can support investor sentiment. Wedbush note Guggenheim note RBC / Benzinga
• Neutral Sentiment: Management presentation at Citi’s 2026 Virtual Oncology Leadership Summit provided additional corporate and program-level color (transcript available) but contained no new timing surprises beyond the company release. Citi Summit Transcript

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.